Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Topical KX-826 in Healthy Males with Androgenetic Alopecia
NCT04984707Phase 1Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pyrilutamide in androgenetic alopecia (AGA) (5 arms), sponsored by Kintor Pharmaceutical Limited. Primary endpoints: Incidence of treatment-emergent adverse events by skin irritation assessments at 3 days, Incidence of treatment-emergent adverse events by vital signs measurements at 3 days and 3 more. Started Jan 2019; status: completed.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT04984707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984707.